The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early and locally advanced NSCLC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials.
H. Hayashi, A. Zer, H. Kenmotsu et al.· ESMO Open· 1 citation
BACKGROUND
MET and angiogenic pathways are activated in EGFR-mutant non-small-cell lung cancer (NSCLC) upon resistance to tyrosine-kinase inhibitors (TKIs). Amivantamab, an EGFR and MET bispecific antibody, is approved in combination with chemotherapy for EGFR-mutant NSCLC post-osimertinib progression based on results...
R. Soo, Sanjay Popat, U. Dafni et al.· The Lancet Respiratory Medic...· 0 citations
Loss of methylthioadenosine phosphorylase (MTAP), which occurs in approximately 10-15% of non-small-cell lung cancers and other solid tumors, represents a key synthetic-lethal vulnerability linking tumor metabolism to epigenetic regulation. MTAP deletion disrupts the methionine salvage pathway, leading to accumulation...
Z. Arter, Joo Sung Shim, C. Park et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.